Four large-scale placebo-controlled outcome trials have studied the effects of sodium–glucose co-transporter-2 (SGLT2) inhibitors in different populations of patients with chronic kidney disease (CKD). The gene discussed is SLC5A2; the disease is chronic kidney disease.